Remove tag share-pricing
article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

On November 22, 2022, the FDA approved CSL Behring’s Hemgenix (etranacogene dezaparvovec), the first gene therapy treatment for hemophilia B, with a staggering manufacturer price of $3.5 million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. The average American with cancer can do the math and come to the same conclusion that some oncology experts are coming to: Cancer drugs are priced too high.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Upcoming sickle cell gene therapies cost effective at $2 million, says ICER

Pharmaceutical Technology

Two gene therapies up for approval this year for sickle cell disease could be cost effective in some cases at a $2 million price point, based on a draft evidence report published by the Institute for Clinical and Economic Review (ICER). Since the price of the therapies is unknown, the institute used a placeholder cost of $2 million.

article thumbnail

Why Rao’s Sauce Is Worth Billions, According to Campbell’s

XTalks

In August, Campbell Soup acquired Rao’s sauce owner Sovos Brands for $23 per share, reflecting a total value of a staggering $2.7 A noteworthy achievement is volume-driven growth, particularly in an era where growth is often price-driven. At $8 per jar, Rao’s sauces come at a much higher price point than fellow Campell’s brand Prego.

article thumbnail

Lyfgenia and Casgevy Become First FDA-Approved Gene Therapies for Sickle Cell Disease

XTalks

The revolutionary CRISPR/Cas9 technology was discovered by Jennifer Doudna and CRISPR Therapeutics co-founder Emmanuelle Charpentier who both shared the 2020 Nobel Prize for it. Vertex-CRISPR’s Casgevy has a US list price of $2.2 Vertex-CRISPR’s Casgevy has a US list price of $2.2 million, despite both having similar efficacy.

article thumbnail

FDA Approval of First Rapid-Acting Oral Depression Drug + Approval of $2.8 Million Gene Therapy for Rare Blood Disorder – Xtalks Life Science Podcast Ep. 75

XTalks

Ayesha shared news about another significant FDA approval for a gene therapy to treat transfusion-dependent beta thalassemia. Hear more about the therapy, some of the setbacks bluebird has had to face on the road to its approval and why the treatment has a steep price tag. Bluebird’s $2.8M

article thumbnail

What challenges does the advanced therapies sector face? 

Drug Discovery World

Joel Eichmann, Co-Founder and Managing Director, Green Elephant Biotech, agrees that prices need to come down significantly for CGT to be widely available. Pricing and reimbursement continues to be a challenge we address as a field. Increased clinical data and evidence of cost-effectiveness can improve coverage.